Novel Flu Vaccine Adjuvant Improves Protection Against Influenza Viruses, Study Finds
Novel Flu Vaccine Adjuvant Improves Protection Against Influenza Viruses, Study Finds
Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus challenges when combined with a mucosal adjuvant that enhances the body’s immune response, according to a study by researchers in the Institute for Biomedical Sciences at Georgia State University.
The study published in the journal ACS Nano shows that immune cell-derived extracellular vesicles, specifically those from mature bone marrow-derived dendritic cells (which are crucial for immune responses), rather than those from immature dendritic cells, are potent mucosal adjuvants for influenza hemagglutinin vaccines.